GLP-1 & compounded medication availability in Arkansas (2026)

Arkansas is one of the quieter states for telehealth-prescribed compounded medications. There are no medication-specific positions from its pharmacy regulators, just ordinary licensure rules doing the work. One detail is worth knowing up front: an online questionnaire alone does not establish care here. A real-time evaluation does. All ten product lines we track are below, each row honest about what ships and what does not.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Arkansas: all ten lines

Availability of all ten OrderlyMeds product lines in Arkansas, with typical delivery times and notes
Product lineAvailable in Arkansas?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Patient-specific prescriptions, filled after a real-time provider evaluation.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days One national price at every dose.
NAD+ Yes 8–10 business days Dispensed by licensed partner pharmacies.
Sermorelin Yes 8–10 business days Same ordering flow as the rest of the longevity family.
Glutathione No N/A Not part of the current OrderlyMeds lineup.
BPC-157 Yes 8–10 business days Compounded injectable. Its federal record sits below.
TB-500 Yes 8–10 business days Compounded injectable; section below carries the federal facts.
KPV No N/A Not carried in any state, injectable-form lines only.
Epitalon Yes 8–10 business days Compounded injectable; see below for the federal status.
MOTS-c Yes 8–10 business days Compounded injectable whose federal entry is its own, below.

Rows marked “No” are deliberate. We publish the gap rather than pad the catalog. Arkansas facts here were last reviewed on November 16, 2026.

Research peptides in Arkansas: BPC-157, TB-500, KPV, Epitalon & MOTS-c

BPC-157, TB-500, Epitalon and MOTS-c are in the Arkansas offering, each as a compounded injectable; KPV is not, since our peptide formulary is injectable-only. Every state page on this site states each line’s own federal record in the same cited words, because a safety fact does not change at a state line. Read the sections below before ordering, available or not.

BPC-157 in Arkansas

Arkansas addresses can order BPC-157 as a compounded injectable, filled on a patient-specific prescription; read the federal facts below first.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Arkansas

Carried for Arkansas as a compounded injectable under a patient-specific prescription. The federal record follows.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Arkansas

KPV is not in the OrderlyMeds formulary, in Arkansas or any state, because these lines are compounded as injectables only.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Arkansas

Offered to Arkansas as a compounded injectable; its federal position is stated below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Arkansas

Compounded as an injectable for Arkansas orders, patient-specific prescription required. Its federal record differs from the other four, so read it as written.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Arkansas’s pharmacy regulators require

Three cited positions below cover the whole Arkansas picture: who oversees the drug-supply chain, how out-of-state pharmacies come under it, and what a telemedicine evaluation must look like.

The Arkansas State Board of Pharmacy, within the Arkansas Department of Health, licenses, permits, and oversees pharmacists, pharmacies, and the distribution system for the sale and delivery of prescription drugs; it has published no GLP-1-specific or peptide-specific compounding position, so its ordinary licensure and compounding rules govern these medications. Source: Arkansas State Board of Pharmacy.

Out-of-state pharmacies that sell or deliver prescription drugs to Arkansas patients fall under the same board permitting and oversight of the drug-distribution system as in-state pharmacies. Source: Arkansas State Board of Pharmacy.

Arkansas permits a professional relationship to be established through a face-to-face examination using real-time audio and visual telemedicine technology, after which noncontrolled medications may be prescribed — but not through an internet questionnaire, an email message, a patient-generated medical history, or text messaging alone. Source: CCHP Policy Finder — Arkansas.

What that adds up to: Arkansas is a straightforward state, with one wrinkle worth knowing: the evaluation itself. An online form alone does not create a provider relationship here; a real-time interaction with an Arkansas-licensed provider does, and that is how OrderlyMeds already works. Fulfillment comes from pharmacies credentialed for Arkansas, at the same national price as every other state.

Arkansas availability FAQs

Is compounded semaglutide available in Arkansas?

Yes. OrderlyMeds ships compounded semaglutide to Arkansas addresses under patient-specific prescriptions, starting at $74/month for the first two months for new customers.

Can I get a prescription in Arkansas from an online form alone?

No. Arkansas expects a real-time audio-visual evaluation to establish care. An internet questionnaire, email, or text thread is not enough on its own. OrderlyMeds’ provider evaluation meets that shape, and the regulator section above cites the policy.

Can I get BPC-157 or other research peptides shipped to Arkansas?

Four of the five ship to Arkansas as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not. Each section above states that line's own federal record.

How long does delivery to Arkansas take?

The published window is 8–10 business days from signup.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone